These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 11181998)

  • 1. Long term analysis of survival in the European randomized trial comparing vinorelbine/cisplatin to vindesine/cisplatin and vinorelbine alone in advanced non-small cell lung cancer.
    Le Chevalier T; Brisgand D; Soria JC; Douillard JY; Pujol JL; Ruffie P; Aberola V; Cigolari S
    Oncologist; 2001; 6 Suppl 1():8-11. PubMed ID: 11181998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A three-arm trial of vinorelbine (Navelbine) plus cisplatin, vindesine plus cisplatin, and single-agent vinorelbine in the treatment of non-small cell lung cancer: an expanded analysis.
    Le Chevalier T; Pujol JL; Douillard JY; Alberola V; Monnier A; Riviere A; Lianes P; Chomy P; Cigolari S; Besson F
    Semin Oncol; 1994 Oct; 21(5 Suppl 10):28-33; discussion 33-4. PubMed ID: 7973766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multicenter randomized trial comparing cisplatin-mitomycin-vinorelbine versus cisplatin-mitomycin-vindesine in advanced non-small cell lung cancer. 'Groupe Français de Pneumo-Cancérologie'.
    Pérol M; Guérin JC; Thomas P; Poirier R; Carles P; Robinet G; Kleisbauer JP; Paillotin D; Vergnenègre A; Balmes P; Touron D; Grivaux M; Pham E
    Lung Cancer; 1996 Feb; 14(1):119-34. PubMed ID: 8696715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of three regimens using vinorelbine (Navelbine) for non-small cell lung cancer.
    Hillner BE; Smith TJ
    Semin Oncol; 1996 Apr; 23(2 Suppl 5):25-30. PubMed ID: 8610234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients.
    Le Chevalier T; Brisgand D; Douillard JY; Pujol JL; Alberola V; Monnier A; Riviere A; Lianes P; Chomy P; Cigolari S
    J Clin Oncol; 1994 Feb; 12(2):360-7. PubMed ID: 8113844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vinorelbine plus cisplatin versus cisplatin plus vindesine and mitomycin C in stage IIIB-IV non-small cell lung carcinoma: a prospective randomized study.
    Gebbia V; Galetta D; Riccardi F; Gridelli C; Durini E; Borsellino N; Gebbia N; Valdesi M; Caruso M; Valenza R; Pezzella G; Colucci G;
    Lung Cancer; 2002 Aug; 37(2):179-87. PubMed ID: 12140141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic evaluation of a randomized clinical trial comparing vinorelbine, vinorelbine plus cisplatin, and vindesine plus cisplatin for non-small-cell lung cancer.
    Smith TJ; Hillner BE; Neighbors DM; McSorley PA; Le Chevalier T
    J Clin Oncol; 1995 Sep; 13(9):2166-73. PubMed ID: 7666075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concurrent radiochemotherapy with vinorelbine plus cisplatin or carboplatin in patients with locally advanced non-small-cell lung cancer (NSCLC) and an increased risk of treatment complications. Preliminary results.
    Semrau S; Bier A; Thierbach U; Virchow C; Ketterer P; Fietkau R
    Strahlenther Onkol; 2003 Dec; 179(12):823-31. PubMed ID: 14652671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of vinorelbine alone or vinorelbine plus cisplatin for stage IV NSCLC.
    Evans WK
    Oncology (Williston Park); 1998 Mar; 12(3 Suppl 4):18-25; discussion 25-6. PubMed ID: 9556779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Do all patients with advanced non-small-cell lung cancer benefit from cisplatin-based combination therapy?
    Soria JC; Brisgand D; Le Chevalier T
    Ann Oncol; 2001 Dec; 12(12):1667-70. PubMed ID: 11843242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study.
    Wozniak AJ; Crowley JJ; Balcerzak SP; Weiss GR; Spiridonidis CH; Baker LH; Albain KS; Kelly K; Taylor SA; Gandara DR; Livingston RB
    J Clin Oncol; 1998 Jul; 16(7):2459-65. PubMed ID: 9667264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential two-line strategy for stage IV non-small-cell lung cancer: docetaxel-cisplatin versus vinorelbine-cisplatin followed by cross-over to single-agent docetaxel or vinorelbine at progression: final results of a randomised phase II study.
    Douillard JY; Gervais R; Dabouis G; Le Groumellec A; D'Arlhac M; Spaeth D; Coudert B; Caillaud D; Monnier A; Clary C; Maury B; Mornet M; Rivière A; Clouet P; Couteau C
    Ann Oncol; 2005 Jan; 16(1):81-9. PubMed ID: 15598943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized study of vinorelbine (VRB) versus vindesine (VDS) in previously untreated stage IIIB or IV non-small-cell lung cancer (NSCLC). The Japan Vinorelbine Lung Cancer Cooperative Study Group.
    Furuse K; Fukuoka M; Kuba M; Yamori S; Nakai Y; Negoro S; Katagami N; Takada Y; Kinuwaki E; Kawahara M; Kubota K; Sakuma A; Niitani H
    Ann Oncol; 1996 Oct; 7(8):815-20. PubMed ID: 8922195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized phase III trial comparing bexarotene (L1069-49)/cisplatin/vinorelbine with cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT I.
    Ramlau R; Zatloukal P; Jassem J; Schwarzenberger P; Orlov SV; Gottfried M; Pereira JR; Temperley G; Negro-Vilar R; Rahal S; Zhang JK; Negro-Vilar A; Dziewanowska ZE
    J Clin Oncol; 2008 Apr; 26(11):1886-92. PubMed ID: 18398154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update: vinorelbine (navelbine) in non-small cell lung cancer.
    Crawford J
    Semin Oncol; 1996 Apr; 23(2 Suppl 5):2-7. PubMed ID: 8610232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The cost-effectiveness of navelbine alone or in combination with cisplatin in comparison to other chemotherapy regimens and best supportive care in stage IV non-small cell lung cancer.
    Evans WK; Le Chevalier T
    Eur J Cancer; 1996 Dec; 32A(13):2249-55. PubMed ID: 9038606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cisplatin/carboplatin + etoposide + vinorelbine in advanced non-small-cell lung cancer: a multicentre randomised trial. Gruppo Oncologico Campano.
    Comella P; Frasci G; De Cataldis G; Panza N; Cioffi R; Curcio C; Belli M; Bianco A; Ianniello G; Maiorino L; Della Vittoria M; Perchard J; Comella G
    Br J Cancer; 1996 Dec; 74(11):1805-11. PubMed ID: 8956797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized study of maintenance vinorelbine in responders with advanced non-small-cell lung cancer.
    Westeel V; Quoix E; Moro-Sibilot D; Mercier M; Breton JL; Debieuvre D; Richard P; Haller MA; Milleron B; Herman D; Level MC; Lebas FX; Puyraveau M; Depierre A;
    J Natl Cancer Inst; 2005 Apr; 97(7):499-506. PubMed ID: 15812075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integration of vinorelbine into chemotherapy strategies for non-small-cell lung cancer.
    Vokes EE
    Oncology (Williston Park); 1995 Jun; 9(6):565-74, 577; discussion 577-8, 581-. PubMed ID: 8719102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Docetaxel: new indication. First-line treatment of non small-cell lung cancer: no advance.
    Prescrire Int; 2005 Feb; 14(75):16-8. PubMed ID: 15751170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.